Evidence map›Paper›PMID 25477170›Full record

ArticleBiomaterials2015

VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo.

Sixiang Shi, Kai Yang, Hao Hong, Feng Chen, Hector F Valdovinos, Shreya Goel, Todd E Barnhart, Zhuang Liu, Weibo Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Nanomedicine in cancer therapy.Signal transduction and targeted therapy · 2023
    Review
  6. Review
  7. Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Anticancer therapeutics: a brief account on wide refinements.American journal of cancer research · 2020
    Review
  14. Review
  15. Optically Active Nanomaterials for Bioimaging and Targeted Therapy.Frontiers in bioengineering and biotechnology · 2019
    Review
  16. Article
  17. Article
  18. Theranostic Probes for Targeting Tumor Microenvironment: An Overview.International journal of molecular sciences · 2017
    Review
  19. Review
  20. Radio-graphene in Theranostic Perspectives.Nuclear medicine and molecular imaging · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sixiang ShiMaterials Science Program, University of Wisconsin-Madison, WI, USA.
Kai YangJiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Institute of Functional Nano and Soft Materials Laboratory (FUNSOM), Soochow University, Suzhou, Jiangsu, China.
Hao HongDepartment of Radiology, University of Wisconsin-Madison, WI, USA.
Feng ChenDepartment of Radiology, University of Wisconsin-Madison, WI, USA.
Hector F ValdovinosDepartment of Medical Physics, University of Wisconsin-Madison, WI, USA.
Shreya GoelMaterials Science Program, University of Wisconsin-Madison, WI, USA.
Todd E BarnhartDepartment of Medical Physics, University of Wisconsin-Madison, WI, USA.
Zhuang LiuJiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Institute of Functional Nano and Soft Materials Laboratory (FUNSOM), Soochow University, Suzhou, Jiangsu, China.
Weibo CaiMaterials Science Program, University of Wisconsin-Madison, WI, USA; Department of Radiology, University of Wisconsin-Madison, WI, USA; Department of Medical Physics, University of Wisconsin-Madison, WI, USA; University of Wisconsin Carbone Cancer Center, Madison, WI, USA. Electronic address: wcai@uwhealth.org.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Novel Combination Therapy for Prostate CancerR01CA169365 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CAI, WEIBO · 2013 to 2015
$903k
NCI NIH HHS 1R01CA169365NCI NIH HHS P30 CA014520NCI NIH HHS P30CA014520NCI NIH HHS R01 CA169365
6 · The paper itself

Abstract

Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its in vivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced in vivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent in vivo stability, specific in vitro and in vivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.

Indexed as

AnimalsCell Line, TumorDrug StabilityFlow CytometryGraphiteHumansHuman Umbilical Vein Endothelial CellsMiceModels, TheoreticalNanoconjugatesOxidesPositron-Emission TomographyReceptors, Vascular Endothelial Growth FactorGraphiteNanoconjugatesOxidesReceptors, Vascular Endothelial Growth FactorGraphene oxide (GO)Positron emission tomography (PET)Vasculature targetingVEGF

Identifiers

PMID25477170
PMCPMC4258896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.